Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLCLANGER, Corey J.International journal of radiation oncology, biology, physics. 2004, Vol 58, Num 3, pp 991-1002, issn 0360-3016, 12 p.Conference Paper

Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challengesLANGER, Corey J.Critical reviews in oncology/hematology. 2012, Vol 83, Num 1, pp 130-144, issn 1040-8428, 15 p.Article

The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancerLANGER, Corey J.Lung cancer. 2001, Vol 34, Num 2, pp 297-303, issn 0169-5002Article

Resectable Non-Small Cell Lung Cancer in the Elderly : Is There a Role for Adjuvant Treatment?LANGER, Corey J.Drugs & aging. 2008, Vol 25, Num 3, pp 209-218, issn 1170-229X, 10 p.Article

Exploring Biomarkers in Head and Neck CancerLANGER, Corey J.Cancer. 2012, Vol 118, Num 16, pp 3882-3892, issn 0008-543X, 11 p.Article

The Lazarus Response in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor MutationLANGER, Corey J.Journal of clinical oncology. 2009, Vol 27, Num 9, pp 1350-1354, issn 0732-183X, 5 p.Article

Targeted Therapy in Head and Neck Cancer : State of the Art 2007 and Review of Clinical ApplicationsLANGER, Corey J.Cancer. 2008, Vol 112, Num 12, pp 2635-2645, issn 0008-543X, 11 p.Article

Staging and prognosis in lung cancer : Making the complex accessibleLANGER, Corey J.Cancer treatment and research. 2001, Vol 105, pp 53-94, issn 0927-3042Article

Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)LANGER, Corey J; MOK, Tony; POSTMUS, Pieter E et al.Cancer treatment reviews. 2013, Vol 39, Num 3, pp 252-260, issn 0305-7372, 9 p.Article

Clinical significance of weight loss in cancer patients : Rationale for the use of anabolic agents in the treatment of cancer-related cachexiaLANGER, Corey J; HOFFMAN, John P; OTTERY, Faith D et al.Nutrition (Burbank, Los Angeles County, Calif.). 2001, Vol 17, Num 1, pp S1-S20, issn 0899-9007, SUPArticle

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitorsLANGER, Corey J; NATALE, Ronald B.Seminars in oncology. 2005, Vol 32, Num 6, pp 23-29, issn 0093-7754, 7 p., SUP10Conference Paper

Standards of care for anemia management in oncology: Focus on lung carcinomaLANGER, Corey J; CHOY, Hak; GLASPY, John A et al.Cancer. 2003, Vol 95, Num 3, pp 613-623, issn 0008-543XArticle

The Evolving Role of Histology in the Management of Advanced Non-Small-Cell Lung CancerLANGER, Corey J; BESSE, Benjamin; GUALBERTO, Antonio et al.Journal of clinical oncology. 2010, Vol 28, Num 36, pp 5311-5320, issn 0732-183X, 10 p.Article

Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancersHERBST, Roy S; LANGER, Corey J.Seminars in oncology. 2002, Vol 29, Num 1, pp 27-36, issn 0093-7754, SUP4Article

Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapyARGIRIS, Athanassios; YI LI; MURPHY, Barbara A et al.Journal of clinical oncology. 2004, Vol 22, Num 2, pp 262-268, issn 0732-183X, 7 p.Article

Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group Study 2598LANGER, Corey J; STEPHENSON, Patricia; THOR, Ann et al.Journal of clinical oncology. 2004, Vol 22, Num 7, pp 1180-1187, issn 0732-183X, 8 p.Article

Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic CarcinomaLEMMA, Girum L; LEE, Ju-Whei; AISNER, Seena C et al.Journal of clinical oncology. 2011, Vol 29, Num 15, pp 2060-2065, issn 0732-183X, 6 p.Article

Phase II Study of the Anti―Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non―Small-Cell Lung CancerKARP, Daniel D; PAZ-ARES, Luis G; JOHNSON, Faye M et al.Journal of clinical oncology. 2009, Vol 27, Num 15, pp 2516-2522, issn 0732-183X, 7 p.Article

Targeted molecular mechanisms of epoetin alfaLANGER, Corey J; HIRSCH, Fred R; CORTES-FUNES, Hernan et al.Lung cancer. 2003, Vol 41, pp S133-S145, issn 0169-5002, SUP1Conference Paper

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trialLANGER, Corey J; MANOLA, Judith; BERNARDO, Patricia et al.Journal of the National Cancer Institute. 2002, Vol 94, Num 3, pp 173-181, issn 0027-8874Article

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic StudyLEONG, Stephen; COHEN, Roger B; O'BRYANT, Cindy et al.Journal of clinical oncology. 2009, Vol 27, Num 26, pp 4413-4421, issn 0732-183X, 9 p.Article

Laryngeal cancer in the United States : Changes in demographics, patterns of care, and survivalHOFFMAN, Henry T; PORTER, Kimberly; KARNELL, Lucy H et al.The Laryngoscope. 2006, Vol 116, Num 9, pp 1-13, issn 0023-852X, 13 p., 2Article

The role of HER2/neu expression and trastuzumab in non-small cell lung cancerHIRSCH, Fred R; LANGER, Corey J.Seminars in oncology. 2004, Vol 31, Num 1, pp 75-82, issn 0093-7754, 8 p., SUP1Article

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapiesHIRSCH, Fred R; SCAGLIOTTI, Giorgio V; LANGER, Corey J et al.Lung cancer. 2003, Vol 41, pp S29-S42, issn 0169-5002, SUP1Conference Paper

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancerLANGER, Corey J; ALBERT, Istvan; SCHREEDER, Marshall T et al.Lung cancer. 2014, Vol 85, Num 3, pp 420-428, issn 0169-5002, 9 p.Article